title: An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anaemia.
authors.affiliation: Hull & East Yorkshire Hospitals NHS Trust, Hull HU16 5JQ, UK.
authors.forename: S
authors.initials: S
authors.lastname: Dixit
authors.affiliation: Hull & East Yorkshire Hospitals NHS Trust, Hull HU16 5JQ, UK.
authors.forename: M
authors.initials: M
authors.lastname: Hingorani
authors.affiliation: Hull and York Medical School, University of York, Heslington, York YO10 5DD, UK.
authors.forename: V
authors.initials: V
authors.lastname: Allgar
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000741:Anemia, Aplastic / Q000139:chemically induced*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide